Investors to look for digital health cos' post-pandemic outlook in Q2 - Cowen

Medavail Holdings

09/07/2021 13:31

(Repeats with no changes to text)
    ** Cowen believes investor focus in Q2 will be on digital
health companies' post-pandemic positioning, as advantages from
COVID-19 subside with vaccinations on the rise
    ** Says for telehealth cos, Q2 has tough y-o-y comparables,
and expects to see heightened integrated care offerings and M&A
activity for other digital players
    ** For Teladoc Health  TDOC.N , brokerage estimates a q-o-q
increase in subscription revenue per member this month, a metric
the brokerage views as a key rev. growth catalyst 
    ** However, brokerage adds that state of visit numbers
beyond the pandemic remains to be seen
    ** Expects American Well's  AMWL.O  visit revenue to decline
in Q2, but says there could be upside from subscription revenue;
also expects telehealth-based pharmacy co MedAvail  MDVL.O  to
report Q2 revenue slightly above consensus estimates
    ** Raises PT on healthcare IT services cos Evolent Health
 EVH.N  to $30 from $25; expects Q2 revenue above Street
estimates, and sees possibility of further upside 
    ** Expects online prescription drug platform GoodRx  GDRX.O 
to report Q2 rev. and adj. EPS in line with Street estimates
    ** TDOC, AMWL, GDRX and MDVL fell between 17% and 52% YTD,
while EVH rose 37.2%

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com))